A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis

Trial Profile

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs AAV RS1 (Primary)
  • Indications Retinoschisis
  • Focus Adverse reactions
  • Sponsors Applied Genetic Technologies Corporation
  • Most Recent Events

    • 08 Jun 2017 According to an AGTC media release, the company will present data at the Macula Society Annual Meeting 2017.
    • 08 Jun 2017 According to an AGTC media release, the company announced topline safety data for the dose escalation phase of this trial.
    • 10 May 2017 According to an AGTC media release, to date, the company has completed dosing in the first three groups. The company expects to provide a data update, across both safety and potential efficacy endpoints, for these first 12 patients this summer. The Data Safety and Monitoring Committee (DSMC) met recently to review the current safety data set including the most recent high-dose group and the Company has initiated enrollment in the expansion group at the high dose.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top